Associated Genetic Biomarkers
Nicastrin (NCSTN) is a gene that encodes a protein that cleaves integral membrane proteins, including Notch receptors and beta-amyloid precursor protein. Missense mutations, synonymous mutations, nonsense mutations, and frameshift mutations are observed in cancers such as stomach cancer, colon cancer, and urinary tract cancer.
NCSTN is altered in 0.52% of all cancers with colon adenocarcinoma, lung adenocarcinoma, mantle cell lymphoma, acute myeloid leukemia, and mature B-cell neoplasm having the greatest prevalence of alterations .
The most common alterations in NCSTN are NCSTN Mutation (0.31%), NCSTN Amplification (0.18%), NCSTN Loss (0.09%), NCSTN K190R (0.05%), and NCSTN T400I (0.17%) .
NCSTN status serves as an inclusion eligibility criteria in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials that contain NCSTN status as an inclusion criterion, 1 is phase 1 (0 open) and 1 is phase 2 (1 open).
Trials with NCSTN status in the inclusion eligibility criteria most commonly target breast carcinoma, cholangiocarcinoma, and colon carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is NCSTN Mutation .
Al101, abemaciclib, carboplatin, cisplatin, and crenigacestat are the most frequent therapies in trials with NCSTN as an inclusion criteria .
Significance of NCSTN in Diseases
Breast Carcinoma +
NCSTN is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NCSTN status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) .
Colon Carcinoma +
Malignant Solid Tumor +
Soft Tissue Sarcoma +
NCSTN is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NCSTN status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.